Latest Articles
Fluorescence-Guided Bladder and Ureter Visualization in Benign Robotic Gynecologic Surgery: A Series of Five Cases - Cureus
Fluorescence-Guided Bladder and Ureter Visualization in Benign Robotic Gynecologic Surgery: A Series of Five Cases Cureus
Published: Dec. 10, 2025, 4:24 a.m.
Stuart Scott Legacy: Memorial cancer research fund helps NC scientists dig into the why of the disease - ABC11
Stuart Scott Legacy: Memorial cancer research fund helps NC scientists dig into the why of the disease ABC11
Published: Dec. 9, 2025, 11:35 p.m.
Mogadishu doctors identify rare C-section scar endometriosis case in Somali patient - hiiraan.com
Mogadishu doctors identify rare C-section scar endometriosis case in Somali patient hiiraan.com
Published: Dec. 9, 2025, 8:43 a.m.
Deep learning-based automated detection of endometrioid endometrial carcinoma in histopathology - Frontiers
Deep learning-based automated detection of endometrioid endometrial carcinoma in histopathology Frontiers
Published: Dec. 8, 2025, 10:41 a.m.
US tech firm sets up European base in Cork with 50 jobs - Cork Beo
US tech firm sets up European base in Cork with 50 jobs Cork Beo
Published: Dec. 8, 2025, 8:21 a.m.
Government blasted for not taking women's health seriously as endometriosis care figures released - Irish Mirror
Government blasted for not taking women's health seriously as endometriosis care figures released Irish Mirror
Published: Dec. 8, 2025, 5:01 a.m.
Bayer launches phase III trial testing Mirena for uterine condition with no treatments - Indian Pharma Post
Bayer launches phase III trial testing Mirena for uterine condition with no treatments Indian Pharma Post
Published: Dec. 7, 2025, 6:02 a.m.
Sharp rise in endometriosis cases alarms Pretoria clinic - The Citizen
Sharp rise in endometriosis cases alarms Pretoria clinic The Citizen
Published: Dec. 5, 2025, 11:04 a.m.
Absci Announces First Participants Dosed In Phase 1/2A Headline Trial - TradingView
Absci Announces First Participants Dosed In Phase 1/2A Headline Trial TradingView
Published: Dec. 4, 2025, 1:24 p.m.
Absci Announces First Participants Dosed in Phase 1/2a HEADLINE™ Trial of AI-Designed Antibody ABS-201™ for Androgenetic Alopecia - The Manila Times
Absci Announces First Participants Dosed in Phase 1/2a HEADLINE™ Trial of AI-Designed Antibody ABS-201™ for Androgenetic Alopecia The Manila Times
Published: Dec. 4, 2025, 1:22 p.m.
Link copied to clipboard!